The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders.
about
Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS)A translation control reporter system (TCRS) for the analysis of translationally controlled processes in the vertebrate cell.Emerging therapeutic strategies for Epstein-Barr virus+ post-transplant lymphoproliferative disorderEverolimus and Malignancy after Solid Organ Transplantation: A Clinical UpdateReview of the proliferation inhibitor everolimus.Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experienceMammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects.Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.Modulation of the cell growth regulator mTOR by Epstein-Barr virus-encoded LMP2A.Rapalogs in viral cancers.Epstein-Barr virus associated polymorphic lymphoproliferative disorders occurring in nontransplant settings.mTOR inhibitors: an overview.Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients.Expression and oncogenic role of Brk (PTK6/Sik) protein tyrosine kinase in lymphocytes.Phosphatase and tensin homolog on chromosome 10 is phosphorylated in primary effusion lymphoma and Kaposi's sarcoma.Novel therapies for patients with chronic myeloid leukemia.RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma.Comparative genome-scale analysis of gene expression profiles in T cell lymphoma cells during malignant progression using a complementary DNA microarray.Detection of protein tyrosine-kinase (PTK) gene expression pattern in normal and malignant T lymphocytes by combined PTK-specific polymerase chain reaction and parallel denaturing gradient gel electrophoresis.Current and future immunosuppressive strategies in renal transplantation.Inhibitors of the mammalian target of rapamycin.Post-transplant lymphoproliferative disorder in liver recipients: Characteristics, management, and outcome from a single-centre experience with >1000 liver transplantations.IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes.Everolimus: an immunosuppressive agent in transplantation.Investigating mammalian target of rapamycin inhibitors for their anticancer properties.Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin.Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas.Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease.Epstein-Barr virus, rapamycin, and host immune responses.Post-transplantation malignancy: a cell autonomous mechanism with implications for therapy.Post-transplant lymphoproliferative disorder after liver transplantation: Incidence, long-term survival and impact of serum tacrolimus level.Critical review of preclinical approaches to evaluate the potential of immunosuppressive drugs to influence human neoplasia.Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy.Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms.Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies.The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy.CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.Post-transplantation malignancies: here today, gone tomorrow?Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management.PI3Kδ inhibition augments the efficacy of rapamycin in suppressing proliferation of Epstein-Barr virus (EBV)+ B cell lymphomas.
P2860
Q24685850-81A12061-F9F6-4D00-AD82-993592BC713BQ25256858-A6C9C61C-8B3F-4AEF-ADE6-CF80D6DFA676Q26859114-EF230A5C-B82F-43AC-A7FC-3A4A24DB0629Q28067598-2028C821-11E1-46E9-AEAC-8BCBFFB0D3CAQ33345496-F6D1CF04-F946-4D30-987E-01AE93A751CCQ33371289-F1768CEF-46C1-4931-BBF8-C2E083931418Q33393707-08898C99-FA85-461D-AD2A-7123E9A50BE8Q33747609-763DA1B3-D66D-44C7-8488-41951724D841Q33754907-849DD36E-92DC-4F91-A362-94B45A61FB53Q34160579-8AD62A59-DE0D-4BD5-A70E-F79562071488Q34220305-F0FEAFD4-DED7-4A7E-B6F7-8E887CBC137BQ34302240-D9ED5E1E-C922-40A3-932F-E26C6171AC1CQ34622755-D1A4A8E7-E134-4E9D-A056-9C12549099F8Q35088231-C8C52220-0B96-46AB-BA56-CA2BBE4C647EQ35235757-E64F33C5-7620-43E4-8261-6054850787ABQ35728742-078039C0-1E3B-41D3-9C41-047EC23FF943Q35832116-A503A02A-5C55-497E-B2A0-56030D9963E0Q35842022-6885C15A-D195-4FF4-BA30-66187FB677DFQ35870285-7BB8EAC6-F2D0-45D8-B884-F45465BC033BQ35906315-1D9F799C-B88E-4274-AC9D-0397E47FAE8AQ36099427-3738F5CD-0728-488F-BD90-FF6B5A01BC67Q36425674-2B31C3F7-DEE8-40FE-8907-E8B02845DBA0Q36445869-A9A84D1E-A65E-4E82-94F9-9403721083FCQ36521866-354ACFC9-FA68-43C7-8863-767CD6EF0177Q36600294-1E0F9D6F-9FD3-4A5B-BF17-ADF70932AC9AQ37028215-8E2CCE3A-C643-4A90-8560-CD877E468B26Q37074284-4193C1D8-D47B-4F25-A4E6-DBB620BA4589Q37248354-7745A795-EFBB-41CC-8A27-E5FB89A93E4EQ37342546-760D2040-0C44-4CCE-A1F9-FF7B701A7769Q37348173-A08E7213-1777-48B0-87FE-6697E13EA291Q37662629-4492B127-18AE-471F-8134-7CBB95BD5E22Q37795414-2663FCF2-316F-4F17-9D69-B7CEC7501129Q37801865-D892C1C4-FFE5-41EC-8211-535FB3E6E543Q38061056-A0169D55-7CA0-4682-BA0A-25B233326D2BQ38112050-18BD14DF-4056-40EB-B642-29326702CD0EQ38195885-7DD86BA5-9D57-4574-B196-E398401F49D7Q38223160-26AE09DD-5F1A-465E-ACA4-D95F0EEB28BFQ38611709-FC5A3E26-6A0A-4ACC-A353-8CC6488B9153Q38833567-B05FF781-0B7D-46B5-8CBE-25ABAC666E5CQ39127814-CFF9164E-F167-42A6-899E-C0D8C113EF6B
P2860
The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
The immunosuppressive macrolid ...... lymphoproliferative disorders.
@ast
The immunosuppressive macrolid ...... lymphoproliferative disorders.
@en
type
label
The immunosuppressive macrolid ...... lymphoproliferative disorders.
@ast
The immunosuppressive macrolid ...... lymphoproliferative disorders.
@en
prefLabel
The immunosuppressive macrolid ...... lymphoproliferative disorders.
@ast
The immunosuppressive macrolid ...... lymphoproliferative disorders.
@en
P2093
P2860
P356
P1476
The immunosuppressive macrolid ...... lymphoproliferative disorders.
@en
P2093
L E Silberstein
M Majewski
P C Nowell
P2860
P304
P356
10.1073/PNAS.080068597
P407
P577
2000-04-01T00:00:00Z